Current and mostly future UDI developments in the EU

2014-RAPS-LogoI gave a presentation on current and future developments in UDI at the RAPS 2014 conference in Austin last week, sitting on a panel on global developments in UDI with presentations on developments also in the US and China.

This will be a short post on the subject of UDI, because most of the information will be in my presentation, which you can view right here:

[slideshare id=39991562&w=476&h=400&sc=no]

As you can see in the presentation and by way of summary, the EU is not doing a lot presently pending the medical devices regulations revision process (which will feature UDI) except undertaking efforts to make sure that the individual member states do not go out on a limb and impose their own national and divergent UDI systems.

The EU will also will be vigilant not to put anything in place that is very different from what the US is putting in place because that would really drive a nasty compliance wedge in the international medical devices market.

When the regulations finally complete, UDI will be phased in for groups of devices based on their risk profile and a lot is still to be implemented by so-called delegated acts. And, of course, if and when UDI will actually work in the EU will also depend on the completion of the Eudamed cathedral.


Navigate through our knowledgebase

Related articles

Article

Regulatory pathways for clean meat in the EU and the US – differences & analogies

Now that the US regulatory framework is shaping up, the analogies and differences with the European regulatory framework for market access for clean meat becomes more and more clear. This blogpost reports these analogies and differences, based on the agreement that the FDA and USDA recently concluded on their cooperation in the field of clean […]

Article

Cannabis derived food products – what’s the current state of play?

Recently, CBD food products were qualified as Novel Foods requiring a market authorization. The lively trade in these products therefore currently seems to be at risk. However, not all cannabis derived products…

Read more

Article

What to expect for 2019 with MDR and IVDR implementation?

Remember the CAMD Roadmap (dating back to end 2017) that promised us a roll-out of MDR and IVDR items that were sometimes even marked ‘high priority’ and how that lifted our spirits (at the time)? Remember how this was supplemented with the Rolling Plan, which promised the roll-out of all roll-outs for 2019? I have […]